We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

This study has been terminated.
(Study was terminated due to low enrollment)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00460460
First Posted: April 16, 2007
Last Update Posted: January 25, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a weekly basis in these diseases.

Condition Intervention Phase
Lymphoma Drug: AZD4877 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open-label, Dose Escalation Study to Assess the Safety, Tolerability & Pharmacokinetics of AZD4877 Administered Once Weekly in Adult Patients With Recurrent or Refractory AML, PH Negative ALL, NHL or MN

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Estimated Enrollment: 75
Study Start Date: March 2007
Study Completion Date: August 2007
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with AML, a certain type of ALL, NHL and MM
  • certain types of cancer of the lymph nodes
  • certain types of leukemias (blood cancers)
  • disease has or will fail with other treatments
  • relatively good overall health other than your cancer

Exclusion Criteria:

  • poor bone marrow function (not producing enough blood cells)
  • serious heart conditions
  • poor liver or kidney function
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00460460


Locations
United States, New York
Research site
Buffalo, New York, United States
Research Site
New York, New York, United States
Canada, Ontario
Research Site
Toronto, Ontario, Canada
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Judith Ochs, MD AstraZeneca
  More Information

ClinicalTrials.gov Identifier: NCT00460460     History of Changes
Other Study ID Numbers: D2782C00002
First Submitted: April 12, 2007
First Posted: April 16, 2007
Last Update Posted: January 25, 2011
Last Verified: January 2011

Keywords provided by AstraZeneca:
Phase I
cancer
lymphoma
leukemia
myeloma
AML
ALL
NHL
MM